Grants per year
Personal profile
Research Interests
Dr. Laumann's clinical interests include the diagnosis and treatment of complex medical dermatologic disorders including collagen vascular, psychocutaneous, and genital diseases. She has a particular interest in fibrosing, pruritic and other disorders related to renal dysfunction, as well as Raynaud's syndrome. She has an ongoing interest in the various aspects of the application of body art and how this may be used to help functioning. Currently, she is involved with other research studies related to psoriasis, atopic dermatitis, nephrogenic systemic fibrosis, systemic sclerosis, morphea, dermatomyositis, and lupus erythematosus.
Certifications and Licenses
| Dermatology |
Training Experience
| 1979 | Residency, University of Chicago Hospitals |
Education/Academic qualification
MRCP (UK), Royal College of Physicians of the UK
… → 1973
MBChB, Birmingham University, England
… → 1968
Research interests
- Dermatology
Fingerprint Dive into the research topics where Anne E Laumann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Body Piercing
Medicine & Life Sciences
Nephrogenic Fibrosing Dermopathy
Medicine & Life Sciences
Skin
Medicine & Life Sciences
Melanoma
Medicine & Life Sciences
Tattooing
Medicine & Life Sciences
Tongue
Medicine & Life Sciences
Dermatomyositis
Medicine & Life Sciences
Drug-Related Side Effects and Adverse Reactions
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2004 2021
Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
ICON Clinical Research, L.P., Gilead Sciences, Inc.
7/27/17 → 7/27/20
Project: Research project
Prot# I1F-MC-RHAZ: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Pati
Parexel, Eli Lilly and Company
4/30/12 → 11/30/19
Project: Research project
Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis
Parexel, Idera Pharmaceuticals, Inc.
3/14/16 → 3/14/19
Project: Research project
Research Output 1975 2019
Association of dermatomyositis with systemic and opportunistic infections in the United States
Ren, Z., Laumann, A. E. & Silverberg, J. I., Jul 5 2019, In : Archives of Dermatological Research. 311, 5, p. 377-387 11 p.Research output: Contribution to journal › Article
Dermatomyositis
Opportunistic Infections
Infection
Inpatients
Adrenal Cortex Hormones
1
Citation
(Scopus)
Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program
Kelm, R. C., Hagstrom, E. L., Mathieu, R. J., Orrell, K. A., Serrano, L., Mueller, K. A., Laumann, A. E., West, D. P. & Nardone, B., Mar 1 2019, In : Journal of the American Academy of Dermatology. 80, 3, p. 820-821 2 p.Research output: Contribution to journal › Article
Drug-Related Side Effects and Adverse Reactions
Melanoma
Research
Natalizumab
5
Citations
(Scopus)
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: An analysis of the National Inpatient Sample
Silverberg, J. I., Kwa, L., Kwa, M. C., Laumann, A. E. & Ardalan, K., Apr 1 2018, In : Rheumatology (United Kingdom). 57, 4, p. 694-702 9 p.Research output: Contribution to journal › Article
Comorbidity
Inpatients
Hospitalization
Lipodystrophy
Cerebrovascular Disorders
History and Epidemiology of Tattoos and Piercings: Legislation in the United States and in Europe
Laumann, AE., Kluger, N. & Perez-Cotapos, ML., 2018, Dermatologic Complications with Body Art Second edition 2018. De Cuyper, C. (ed.). Heidelberg: Springer, p. 1-19Research output: Chapter in Book/Report/Conference proceeding › Chapter
7
Citations
(Scopus)
Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program
Orrell, K. A., Murphrey, M., Kelm, R. C., Lee, H. H., Pease, D. R., Laumann, A. E., West, D. P. & Nardone, B., Oct 1 2018, In : Journal of the American Academy of Dermatology. 79, 4, p. 777-778 2 p.Research output: Contribution to journal › Article
LY2439821
Interleukin-17
Drug-Related Side Effects and Adverse Reactions
Inflammatory Bowel Diseases
Research